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Research
Some ortho-phthalates, including di(2-ethyl-
hexyl) phthalate (DEHP) and di-n-butyl 
phthalate (DBP), have been identified as repro-
ductive and developmental toxicants in labora-
tory animals (Foster 2005; Howdeshell et al. 
2008). Similar effects have not been reported 
in animals exposed to diethyl phthalate (DEP); 
however, limited human studies have suggested 
a possible association between DEP expo-
sure and male reproductive health outcomes 
(Swan 2008). Studies have shown widespread 
population exposure to background levels of 
phthalates (Silva et al. 2004). Of concern, 
particularly high exposure levels may result 
from orally ingested medicinal products con-
taining phthalates as inactive ingredients. For 
example, increased urinary concentrations of 
phthalate metabolites were first reported for 
an individual taking a mesalamine product 
(Asacol; Warner Chilcott Pharmaceuticals 
Inc., Mason, OH) (Hauser et al. 2004) and 
later confirmed for individuals taking mesala-
mine and other drug products (Hernández-
Díaz et al. 2009). High urinary concentrations 
of phthalate metabo  lites have also been identi-
fied in patients with cystic fibrosis who used 
pancreatic enzyme products (Keller et al. 
2009). This has led to increased interest in 
identifying additional drug products that con-
tain phthalates as   inactive ingredients.
Inactive ingredients (excipients) are defined 
as “any component other than the active ingre-
dient in a drug product” (FDA 2011). These 
various compounds may be used in drug for-
mulations for a number of functions related 
to the preparation and stability of the physical 
dosage form or the delivery of active ingredi-
ents (Rowe et al. 2009). Excipients used in spe-
cialized drug product formulations may permit 
a) localized availability of active medications 
in various sections of the gastro  intestinal (GI) 
tract, b) controlled release of a medication over 
time, or c) through the skin. Phthalates, in 
combination with various polymers, may be 
used as plasticizers and film coating agents in 
orally ingested solid pharmaceutical dosage 
forms and in numerous types of modified-
release drug delivery systems such as enteric-
coated and delayed-release tablets, pelletized 
delayed-release capsules, enteric-coated cap-
sules, and controlled-release trans  dermal films 
(Allen et al. 2005).
Several different phthalates are currently 
used as excipients in approved pharmaceutical 
formulations: diethyl phthalate (DEP), 
dibutyl phthalate (DBP), dimethyl phthalate 
(DMP), dioctyl  phthalate (DOP), hypromellose 
phthalate (HMP), cellulose acetate phthalate 
(CAP), poly  vinyl acetate phthalate (PVAP), 
and poly  ethylene terphthalate (PET) [Food and 
Drug Administration (FDA) 2010b]. These 
compounds are not themselves technically 
“approved” for general use as excipients; 
rather, they are permitted to be included in 
their corresponding approved drug products, 
with maximum levels designated for each 
type of dosage form and route of adminis  tra-
tion (Osterberg and See 2003; Steinberg and 
Silverstein 2003). The maximum amount of 
DBP used in specific FDA-approved drug 
products ranges from 1.70 mg for a delayed-
action, enteric-coated tablet formulation 
to 11.18 mg for an extended-release capsule 
product. DEP has been approved at amounts 
ranging from 0.5 mg for an uncoated, chewable 
tablet to 16.8 mg for a delayed-action, enteric-
coated capsule (FDA 2010b).
Nonprescription pharmaceutical (over-
the-counter; OTC) and dietary supplement 
products may contain excipients found in 
approved prescription (RX) products; however, 
their composition is not always reviewed prior 
to marketing. OTC drug products marketed 
under monograph guidelines do not require 
pre  market review of their ingredients, but con-
tents are reviewed for products approved under 
new drug applications (NDAs) and abbrevi-
ated NDAs (ANDAs) (FDA 2010a). Dietary 
supplements are regulated as food products 
under the Dietary Supplement Health and 
Education Act of 1994 (DSHEA 1994), and 
their formulations do not require approval 
prior to marketing unless they contain a new 
dietary ingredient (FDA 2009).
Manufacturers are required to disclose a 
listing of inactive ingredients in drug prod-
uct labeling, except when they are used in 
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Ba c k g r o u n d: In animal studies, some ortho-phthalates, including di(2-ethylhexyl) phthalate 
(DEHP) and di-n-butyl phthalate (DBP), have been shown to be reproductive and develop  mental 
toxi  cants. Human studies show widespread population exposure to background levels of phthalates. 
Limited evidence suggests that particularly high exposure levels may result from orally ingested 
medicinal products containing phthalates as excipients (inactive ingredients).
oB j e c t i v e: In this study we aimed to identify and describe the scope of prescription (RX) and non-
prescription (over-the-counter; OTC) medicinal products and dietary supplements marketed in the 
United States and Canada since 1995 that include phthalates as excipients.
Me t h o d s : We used lists of modified-release drug products to identify potential drug products. 
Inclusion of phthalates was verified using available electronic databases, print references, published 
package inserts, product packages, and direct communication from manufacturers. Additional prod-
ucts were identified using Internet searches utilizing keywords for phthalates.
re s u l t s: Based on labeling information, 6 RX drug products included DBP as an excipient, and 
45 specified the use of diethyl phthalate (DEP). Phthalate polymers with no known toxicity—
hypro  mellose phthalate (HMP), cellulose acetate phthalate (CAP), and polyvinyl acetate phthalate 
(PVAP)—were included in 75 RX products. Three OTC drug and dietary supplement products 
listed DBP, 64 listed DEP, and > 90 indicated inclusion of polymers.
co n c l u s i o n s: Numerous RX and OTC drug products and supplements from a wide range of 
therapeutic categories may use DBP or DEP as excipients in oral dosage forms. The potential effects 
of human exposure to these phthalates through medications are unknown and warrant further 
investigation.
key w o r d s : coating, dietary supplements, excipients, medications, phthalates. Environ Health 
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patented delivery mechanisms where the 
composition is considered to be a confidential 
trade secret (U.S. Pharmacopeial Convention 
2009). Although the FDA might have infor-
mation on the type and amount of phthalates 
used in specific approved drug products, they 
cannot make the information public because 
of its proprietary nature.
In this study we sought to identify and 
describe the scope of medicinal pharmaceuti-
cal products and dietary supplements mar-
keted in the United States and Canada since 
1995 that could be confirmed to contain 
phthalates as excipients based on available 
product information supplied by regulators, 
manufacturers, labelers, distributors, and mar-
keters of these products.
Methods
A search of the published literature on the 
use of phthalates in orally ingested medica-
tions suggested that phthalates are frequently 
included as inactive ingredients in modified-
release drug formulations (i.e., controlled-
release, delayed-release, or targeted-release 
systems), as well as in formulations for film 
coatings. Drug products using these formu-
lations rely on the integrity of their coating 
systems for proper delivery of their active 
ingredients and therefore should not be 
crushed or chewed. Lists of drug products 
that are not recommended to be crushed 
or chewed have been published for refer-
ence by health care professionals to ensure 
their proper administration (Mitchell 2011; 
Thomson PDR 2006). We used these lists, 
which included approximately 450 product 
names, to complete an initial screen of drug 
product labeling for the inclusion of phtha-
lates as excipients.
All inactive ingredients for RX medications 
on the “do not crush list” were first reviewed 
using a combination of print and electronic 
resources including the Physicians’ Desk 
Reference (Thomson Healthcare 1995–2010a), 
FDA Approved Drug Products database 
(Drugs@FDA; FDA 2011b), DailyMed 
[National Library of Medicine (NLM) 2011a], 
and LabelDataPlus (Reed Technology and 
Information Services Inc. 2011). Canadian 
products with comparable active ingredients 
and formulations were researched by using 
any available monographs from the Health 
Canada Drug Product Database (Health 
Canada 2011a) and the CPS: Compendium 
of Pharmaceuticals and Specialties (Canadian 
Pharmaceutical Association 1995–2006). 
Names of brand and generic drug products 
marketed since 1995 appearing on the lists 
were searched within each available electronic 
or print reference, and all potential modified-
release formulations were selected from the 
results. Once a label was located, we searched 
the document for all inactive ingredients. 
If multiple labels were available within a 
database, we investigated all potential inactive 
ingredient formulation changes by reviewing 
the older labels. If an older formulation of 
the product contained phthalates but the 
newer formulations did not, we searched all 
available labels by revision date to determine 
when the formulation changed. If none of the 
available compendia provided sufficient label 
information for a product, we searched the 
manufacturer or distributor website. If no label 
was found, we contacted the manufacturer and 
requested a copy of the package insert. 
We performed further Internet searches 
using terms containing “phthalate” and 
“medi  cation,” or suspected medication names 
and drug classes (e.g., bisacodyl, enzyme), to 
locate additional products and product cate-
gories. Patents for proprietary drug delivery 
systems were reviewed for the use of phthalate 
plasticizers in specific drug products or groups 
of products.
Several OTC medications and dietary 
supplement products were listed on the “do 
not crush” list; however, most available refer-
ences including the Physicians’ Desk Reference 
for Nonprescription Drugs, Dietary Supplements, 
and Herbs (Thomson Healthcare 1995–2010b), 
Drugs@FDA, LabelDataPlus, DailyMed, and 
Dietary Supplements Labels Database (NLM 
2011b) either did not include these products or 
did not provide complete, searchable label infor-
mation on their inactive ingredients. For these 
products, we obtained detailed information on 
inactive ingredients from manufacturer and dis-
tributor web sites, or if possible, directly from 
product package labeling retrieved from store 
shelves. Canadian dietary supplement prod-
ucts were searched using the Health Canada 
Licensed Natural Health Products Database 
(LNHPD; Health Canada 2011b), which cur-
rently contains information on approximately 
16,000 licensed dietary supplements available 
in solid oral dosage forms.
Results
Use in prescription drugs. Various phthalates 
were identified in RX medications available 
in the United States and Canada across a wide 
variety of therapeutic classes, including anal-
gesic, anti  biotic, GI, cardio  vascular, and anti-
epileptic drug products. As expected, we found 
that phthalates were most commonly used in 
modified-release RX drug formulations that 
provided timed-release and targeted-re  lease of 
active ingredients. Of the RX products that 
were identified, 75 contained the phthalate 
polymers HMP, CAP, and PVAP (data not 
shown), and 50 contained the ortho-phthalates 
DEP and/or DBP (6 contained DBP, and 
1 contained both DEP and DBP) (Table 1). 
Use in OTC drugs and dietary supple-
ments. Enteric coatings, film coatings, and 
specialized capsule formulations utilizing 
phthalates were noted for a number of dif-
ferent product categories and purposes in 
OTC drugs and supplements. These functions 
included prevention of premature degradation 
of substances such as enzymes, acid reducers, 
and probiotics by stomach acid; reduce stom-
ach upset from iron and laxatives; minimize 
the aftertaste from fish oil and garlic; and pro-
duce soft gelatin capsules (i.e., “softgels”) that 
may be easier to swallow or contain solubilized 
drugs and oils (e.g., ibuprofen, fish oil).
Thirty-eight of the OTC drug products 
(Table 2) and 24 of the dietary supplement 
products (Table 3) located listed DEP, and 
93 included phthalate polymers (data not 
shown). Although there were only 3 ANDAs 
for OTC ranitidine detailing the use of DEP, 
they were linked to label information for an 
additional 31 private label antacid products. 
Only 1 OTC drug available both in the United 
States and Canada [Dulcolax Laxative Tablets 
(Boehringer Ingelheim Pharmaceuticals, 
Ridgefield, CT, USA; and Boehringer 
Ingelheim (Canada) Ltd./Ltée, Burlington, 
Ontario, Canada] and 2 older formulations 
of dietary supplement products listed DBP 
[Venastat Leg Vein Health (Boehringer 
Ingelheim Pharmaceuticals) and Wobenzym N 
(Mucos Pharma, Průhonice, Czech Republic)]. 
Canada. Several RX and OTC medica-
tions approved for use in both the United 
States and Canada contained the same inac-
tive ingredients in the product labeling (e.g., 
Asacol, Dulcolax) (Tables 1 and 2); however 
there were some differences. Of particular 
note, the U.S. product labeling for Vivotif 
(Typhoid Vaccine Live Oral Ty21a) (Berna 
Biotech Ltd. 2006) did not detail the use of 
any phthalates, whereas the monograph for the 
Canadian product (Crucell Switzerland LTD 
2010) specified use of “3–8 mg” of DBP and 
DEP and “27–33 mg” of HMP in the lacquer 
coating of each capsule. Several U.S. products 
were not available in Canada (e.g., Cardizem 
CD 360 mg, Dilt-CD), and some Canadian 
products were not distributed in the United 
States (e.g., Rhotral, Parsitan). In the LNHPD 
(Health Canada 2011b), 49 licensed supple-
ment products were linked to phthalates as 
non  medicinal ingredients, including 14 noted 
as containing DEP (Table 3).
Changes over time. A handful of prod-
ucts changed the use of specific excipients over 
time either by removing specific phthalates or 
adding phthalates to newly approved formula-
tions. Solvay Pharmaceuticals removed DBP 
from its new FDA-approved formulations of 
pancrelipase capsules in April 2009. The older 
formulation, Creon Minimicrospheres, (Solvay 
Pharmaceuticals Inc. 2006), which contained 
DBP and HMP, was replaced with Creon 
Delayed Release Capsules (Abbott Laboratories 
2011). New formulations for two strengths 
of OTC and RX ranitidine tablets from Phthalates in medications and supplements
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Table 1. Prescription drug products marketed in the United States and Canada listing ortho-phthalates as inactive ingredients in product labeling, 1995–2011.
Generic name Trade namea Labeler/manufacturer Phthalate  Drug class 
Acebutolol Rhotral 400 mg tablets (Canada)
(discontinued 2006)
Rhodiapharm (Canada) DEP Cardiovascular/beta blocker
Carbamazepine Carbamazepine 200 mg tablet Teva Pharmaceuticals USA Inc. DEP Antiepileptic
Taro-Carbamazepine CR (Canada) Taro Pharmaceuticals Inc. (Canada) DEP
Cyclobenzaprine Amrix Cephalon Inc. DEP Muscle relaxant
Cyclobenzaprine HCl Extended 
Release Capsules
CIMA Labs Inc./Eurand DEP
Didanosine Didanosine, Enteric Coated Aurobindo Pharma Ltd. DEP Antiretroviral
Didanosine, Enteric Coated Mylan Pharmaceuticals Inc. DEP
Videx EC (United States and Canada) Bristol Myers Squibb Co./Bristol Myers Squibb Canada DEP
Diltiazem Cardizem CD 360 mg Capsule BTA Pharmaceuticals Inc. DEP Cardiovascular/CCB
Dilt-CD Apotex Corp. DBP
Diltiazem Extended Release (Twice-
A-day)
Mylan Pharmaceuticals Inc. DEP
Divalproex Divalproex sodium tablet, delayed 
release
Aurobindo Pharma Limited DEP Antiepileptic
Divalproex sodium tablet, delayed 
release
Greenstone LLC/Aurobindo Pharma DEP
Erythromycin ERYC (Canada) Pfizer Canada Inc. CAP, DEP Antibiotic
Ethopropazine Parsitan (Canada) Rhone-Poulenc Rorer/Erfa Canada Inc. DEP Antiparkinsons
Galantamine Razadyne ER Ortho-McNeil Neurologics DEP Antiparkinsons
Galantamine HBr Extended Release 
Capsules
Global Pharmaceuticals/Impax Laboratories Inc. DEP
Reminyl ER (Canada) Janssen-Ortho Inc. DEP
Isosorbide Isosorbide Mononitrate, tablet 
extended release
Torrent Pharmaceuticals Ltd. DEP Cardiovascular/vasodilator
Ketoprofen Nu-Ketoprofen E (Canada) Nu-Pharm (Canada) CAP, DEP NSAID
Orudis SR (Canada) (discontinued 
2005)
Aventis Pharma (Canada) CAP, DEP
Mesalamine Asacol (United States and Canada) Warner Chilcott US LLC/Warner Chilcott Canada Co. DBP GI/anti-inflammatory
Asacol HD Warner Chilcott US LLC. DBP
Asacol 800 (Canada) Warner Chilcott Canada Co. DBP
Salofalk 500 mg Enteric Coated 
(Canada)
Axacan Pharma Inc. DEP
Morphine sulfate Kadian Actavis Kadian; Alpharma Branded Products DEP Analgesic
Morphine Sulfate Extended Release 
Capsules
Actavis Elizabeth LLC DEP
Morphine sulfate/naltrexone Embeda King Pharmaceuticals/Actavis DEP Analgesic
Pancrelipase Cotazym ECS (OTC in Canada) Organon Canada Ltd./Schering-Plough Canada Inc. CAP, DEP GI/enzyme
Creon Minimicrospheres Solvay Pharmaceuticals Inc. DBP, HMP
Lipram Eurand America DEP, HMP
Pancrease McNeil CAP, DEP
Pancrecarb Digestive Care Inc. CAP, DEP
Potassium chloride Potassium Chloride Extended Release 
Tablets, USP
American Health Packaging/Watson/Eurand DEP Potassium supplement
Riva-K 20 SR (Canada) Laboratories Riva Inc. (Canada) DEP
Prochlorperazine Stemetil tablets (Canada) 
(discontinued 2005)
Rhone-Poulenc Rorer/Aventis Pharma DEP Antiemetic
Propranolol InnoPran XL GlaxoSmithKline DEP, HMP Cardiovascular/beta blocker
Ranitidine Ranitidine Tablets, USP 150 mg Wockhardt USA, LLC DEP GI/antiulcer-H2 Blocker
Ranitidine Tablets, USP 300 mg Wockhardt USA, LLC DEP
Sulfasalazine Sulfasalazine Delayed Release 
Tablets, USP
Vintage Pharmaceuticals CAP, DEP GI/anti-inflammatory
Sulfazine EC Qualitest/Vintage Pharmaceuticals-Charlotte CAP, DEP
Theophylline Theo-Dur Extended Release Tablets Key Pharmaceuticals CAP, DEP Respiratory/bronchodilator
Uni-Dur Extended Release Tablets Key Pharmaceuticals CAP, DEP
Thioproperazine mesylate Majeptil (Canada) Rhone-Poulenc Rorer/Erfa Canada Inc. DEP Antipsychotic
Trimipramine Rhotrimine Tablets (Canada)
(discontinued 2006)
Rhodiapharm (Canada) DEP Antidepressant
Typhoid vaccine, oral Vivotif (Canada) Crucell Switzerland Ltd. DBP, DEP, HMP Vaccine
Valproic acid ratio-Valproic 500 mg Capsules 
(Canada)
ratiopharm (Canada) CAP, DEP Antiepileptic
phl-Valproic Acid 500 mg Capsules 
(Canada)
Pharmel Inc. CAP, DEP
Verapamil Verapamil HCL Extended Release 
Capsules
Mylan Pharmaceuticals Inc. DEP Cardiovascular/CCB
Verapamil HCL PM Extended Release 
Capsules
Mylan Pharmaceuticals Inc. DEP
Abbreviations: CCB, calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug.
aApplies to all strengths and dosage forms unless otherwise noted. Kelley et al.
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one manufacturer (Wockhardt USA LLC, 
Parsippany, NJ) that were approved in 2007, 
2008, and 2009 (Wockhardt USA LLC 2007, 
2008, 2009) used DEP as a film coating agent, 
whereas labels for > 30 earlier approved raniti-
dine products did not list any phthalates. 
In May 2010, Warner Chilcott modified 
the labeling for Asacol and Asacol HD under 
the sections “Precautions” and “Use in Specific 
Populations.” The new labels provided cau-
tions on use during pregnancy based on animal 
studies of DBP exposure and also added the 
estimated human daily intake of DBP from the 
maximum recommended daily dose of each 
product, “about 21 mg” and “about 48 mg” for 
Asacol and Asacol HD, respectively (Warner 
Chilcott Pharmaceuticals Inc. 2010a, 2010b) 
Use in specific formulations. Inclusion 
of phthalates—as well as the specific type of 
phthalate—in formulations for a particular drug 
was manufacturer specific, and on occasion dos-
age-form and strength specific. For example, 
the calcium channel blockers verapamil and 
diltiazem were available from 18 manufacturers 
in a number of strengths and time-release tablet 
and capsule formulations that contained differ-
ent excipients. Although we found that DEP 
was included in two verapamil extended-release 
capsule products, both from one manu  facturer 
(Mylan Pharmaceuticals Inc. 2010a, 2010b), 
other tablet and capsule formulations did not 
contain DEP. Among diltiazem products, only 
one of five strengths of Cardizem CD cap-
sules (BTA Pharmaceuticals Inc. 2010) listed 
DEP, whereas manufacturers of other specific 
diltiazem capsule products utilized phthalates 
across all strengths: DBP in Dilt-CD (Apotex 
Inc. 2011), DEP in Diltiazem Extended-
Release, Twice-A-Day (Mylan Pharmaceuticals 
Inc. 2006), and HMP in Diltia XT (Watson 
Pharma Inc. 2008).
Other sources of information. Detailed 
Internet searches led to the identification of 
two phthalate-containing products in patented 
release mechanisms, despite the fact that 
phthalates were not listed in the correspond-
ing product labels. In a lawsuit brought against 
several manufacturers attempting to introduce 
new generic omeprazole products into the 
market in 2001, the manufacturer of Prilosec 
Delayed Release Capsules (AstraZeneca 
Pharmaceuticals LP, Wilmington, DE) argued 
that the new formulations infringed on cer-
tain sections of their patent involving the 
use of phthalates, including DEP and HMP, 
as coating agents (Astra Aktiebolag et al. v. 
Andrx Pharmaceuticals Inc., et al., 2002). 
Communication with the manufacturer 
(AstraZeneca, personal communication) con-
firmed the use of HMP in the enteric coating 
layer of the pelletized drug found within the 
capsules. A similar patent infringement case 
(Shire LLC v. Nostrum Pharmaceuticals Inc. 
2008) detailed the use of HMP in patents 
for carbamazepine extended release capsules 
(Carbatrol; Shire US Inc., Wayne, PA). 
Table 2. Nonprescription drugs products marketed in the United States and Canada listing ortho-phthalates as inactive ingredients in product labeling, 1995–2011.
Generic name Trade namea Labeler/manufacturer Phthalate  Drug class 
Brompheniramine Dimetane Allergy Extentabs Whitehall-Robins CAP, DEP Antihistamine
Aspirin-delayed release Entrophen ECT 975 mg (Canada) Pendopharm, Division of/de Pharmascience Inc (Canada) CAP, DEP Analgesic/antipyretic
Enteric Coated A.S.A. (Canada) Pendopharm, Pharmascience (Canada) CAP, DEP, PVAP
Bisacodyl Dulcolax Bisacodyl Laxative Tablets Boehringer Ingelheim DBP GI/laxative
Dulcolax ECT 5 mg (Canada) Boehringer Ingelheim Canada Ltd. DBP
Omeprazole Omesec Delayed Release Capsules Corporation Infarmasa DEP, HMP GI/antiulcer-PPI
Ranitidine Ranitidine 75 mg (Wockhardt)b  Wockhardt USA LLC DEP GI/antiulcer-H2 blocker
Ranitidine 150 mg (Wockhardt)c  Wockhardt USA LLC DEP
Ranitidine 75 mg (Wockhardt)d  Wockhardt USA LLC DEP
Berkley & Jensen Acid Reducer 150 mgc  BJWC DEP
Care One Acid Reducer 75 mgb  American Sales Company DEP
CVS Maximum Strength Acid Reducerc  CVS Pharmacy DEP
DG Health Acid Reducer 75 mgb  Dolgencorp Inc. DEP
DG Health Acid Reducer 150 mgc  Dolgencorp Inc. DEP
Equaline Acid Reducer Ranitidine 150 mgc  Supervalu Inc. DEP
Equaline Heartburn Relief 75 mgb  Supervalu Inc. DEP
Formucare Ranitidine 75b  Access Business Group International LLC DEP
Good Neighbor Acid Reducer 150 mgc  Amerisource Bergen DEP
Good Neighbor Acid Reducer 75 mgb  Amerisource Bergen DEP
Goodsense Acid Reducer 150 mgc  L Perrigo Company DEP
Goodsense Acid Reducer 75 mgb  L Perrigo Company DEP
Kirkland Signature Acid Reducerc  Costco Wholesale Corporation/Perrigo DEP
Kroger Heartburn Relief 75 mgb  Kroger Company DEP
Leader Acid Control 75 mgb  Cardinal Health DEP
Leader Acid Control 150 mgc  Cardinal Health DEP
Major Ranitidine 150 Maximum Strengthc  Major Pharmaceuticals DEP
Major Ranitidine 75b  Major Pharmaceuticals DEP
Medicine Shoppe Acid Reducer 75 mgb  Medicine Shoppe International DEP
Meijer Acid Reducer 75 mgb  Meijer Distribution Co DEP
Publix Acid Reducer 75 mgb  Publix Super Markets Inc. DEP
Safeway Acid Reducer 150 mgc  Safeway DEP
Safeway Acid Reducer 75 mgb  Safeway DEP
Sunmark Acid Reducer 150 mgc  McKesson DEP
Sunmark Acid Reducer 75 mgb  McKesson DEP
TopCare Heartburn Relief 75 mgb  Topco Associates LLC DEP
TopCare Heartburn Relief 150c  Topco Associates LLC DEP
UP & UP Acid reducer 75 mgb  Target DEP
Wal-Zan 75 Acid Reducerb  Walgreens/Perrigo DEP
Wal-Zan 150 Acid Reducerc  Walgreens/Perrigo DEP
Western Family Foods Acid Relief 75 mgb  Western Family Foods Inc. DEP
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor.
aApplies to all strengths and dosage forms unless otherwise noted. bANDA 076760; manufacturer, Wockhardt, Mumbai, India. cANDA 078653; manufacturer, Wockhardt, Mumbai, India. 
dANDA 078884; manufacturer, Wockhardt, Mumbai, India. Phthalates in medications and supplements
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Discussion
In this study, we identified a number of dif-
ferent phthalates as excipients in a variety of 
pharmaceutical products and dietary supple-
ments sold in the United States and Canada. 
Although most of these products included 
phthalate polymers that are considered to be 
of low or no known toxicity, label informa-
tion for several product formulations con-
tained the phthalate diester DBP, which has 
been shown to cause adverse effects in experi-
mental animal studies.
Although we attempted to review as many 
product listings as possible, this list cannot 
be considered comprehensive. Information 
on a number of products was unavailable 
due to product discontinuation and changes 
in manufacturers. Products may have 
changed their formulation over time, and 
the information available at the time of this 
review may not reflect the most recent version 
of the product formulation. In addition, 
some product information was incomplete 
(all inactive ingredients were not listed), 
which required that we seek information 
directly from the manufacturer. Although 
the FDA might have a more complete listing 
of products, including the type and amount 
of phthalate in specific drug products, this 
information is considered proprietary and 
cannot be accessed. Given the thousands 
of orally ingested products on the market 
(RX, OTC, and dietary supplements), it 
is difficult to quantify the prevalence of 
phthalate-containing products. However, 
it is informative to identify specific drug 
products that have included phthalates in their 
formulations.
It is also important to note the limitations 
and difficulties that were associated with some 
of the references used to compile the informa-
tion for this study. Information on the specific 
excipients used in these products was generally 
available; however, it was not centrally located, 
comprehensive, or easily queried.
The FDA Approved Drug Products 
Database (Drugs@FDA) did not contain 
labels for all products, especially generics, and 
only some entries contained copies of approval 
history documents that detail product formu-
lations. Several additional labels were available 
on LabelDataPlus, DailyMed, or manufac-
turer web sites, demon  strating that electronic 
versions of the labels were available but were 
not linked to the FDA database. For example, 
detailed label information for prescription and 
OTC ranitidine tablets from Wockhardt was 
available on DailyMed and LabelDataPlus 
but not on Drugs@FDA. The available OTC 
labels linked these approved products to label-
ing for several private label distributors (e.g., 
mass merchandise, grocery and drug store 
chains); however, these labelers and distribu-
tors often change the source for their private-
label products over time. Neither Drugs@FDA 
nor Health Canada’s Drug Product Database 
permitted a systematic search of excipients in 
RX and OTC drug products. LabelDataPlus 
permitted queries for inactive ingredients; 
however, it was not comprehensive. 
The Physicians’ Desk Reference (Thomson 
Healthcare 1995–2010a) contained some 
additional product labels, especially older 
versions of labels and discontinued products 
(e.g., Theo-Dur; Key Pharmaceuticals Inc., 
Kenilworth, NJ); however, available informa-
tion was limited to manufacturers who elected 
to include their products in the reference.
We found several NDAs and ANDAs 
containing information on excipients using 
Drugs@FDA. However, because of the pro-
prietary nature of the formulations, in most 
instances information concerning the type 
and amount of inactive ingredients used were 
redacted from the available documents. In 
LabelDataPlus, the strength of each inactive 
ingredient was provided for one omepra-
zole product—Omesec Delayed Release 
Capsules—listed as containing 0.144 mg DEP 
(Corporacion Informasa 2010); however, this 
was the only drug product for which we found 
this level of information to be available.
For a number of dietary supplement 
products, the available information on inac-
tive ingredients was incomplete or unclear. 
Available label information sometimes 
described products as having an “enteric coat-
ing” without a specific listing of the com-
ponents, making it impossible to determine 
whether any phthalates were present. Some 
fish oil capsules labels stated that they “may 
also contain” a variety of excipients, including 
HMP. Canada’s LNHPD (Health Canada 
2011b) and the NLM Dietary Supplements 
Labels Database permitted searches by inactive 
ingredients for licensed health products and 
supplements, but these databases are not com-
prehensive directories of marketed products.
Table 3. Dietary supplements marketed in the United States and Canada listing ortho-phthalates as inactive ingredients in product labeling, 1995–2011.
Generic name Trade name Manufacturer/distributor Phthalate Supplement type
Fish oil Omega 3+ Enteric Coated Fish Oil Health Thru Nutrition/Epic4Health DEP, HMP Nutritional
Phyto-Therapy Omega 3 MLC Fish Oil, Enteric coated Phytotherapy USA DEP, HMP
Garlic Walgreens Finest Natural Garlic, tablets Walgreens DEP Herbal
Wholehealth GarlicHealth, Odorless Garlic Wholehealth CAP, DEP
Nikken Garlic (Bio-Directed Nutri-Technology) Nikken CAP, DEP
Planetary Herbals GarliChol Planetary Herbals CAP, DEP
Top Care Garlic Tablet Perrigo DEP
Ail Garlic (Canada) Lyo-San Inc. (Lachute, Quebec, Canada) CAP, DEP
Magnesium Slow-Mag Magnesium Chloride with Calcium Purdue Products LP DEP Mineral
Vitamin B Tri-Phos-B Montiff Inc. CAP, DEP Vitamin
Vitamin C Viva Vitamin C 500 mg tablets (Canada) Viva Pharmaceutical Inc. (Canada) DEP Vitamin
Viva Vitamin C 1,000 mg tablets (Canada) Viva Pharmaceutical Inc. (Canada) DEP
Probiotics Advanced Naturals Ultimate FloraMAX (Canada) Renew Life Canada Inc. CAP, DEP Probiotic
Acidophilus Complex with FOS (Canada) WN Pharmaceuticals Ltd. (Canada) CAP, DEP
Dophilus Select Plus (Canada) Les Importations Biochala Inc. (Canada) CAP, DEP
Swiss Natural 5 Strain Dophilus Capsules (Canada) Swiss Herbal Remedies Ltd./TheraPro (Canada) CAP, DEP
Primadophilus Reuteri (Canada) Nature’s Way of Canada Ltd. CAP, DEP
Bifidus (Canada) Lyo-San Inc. (Canada) CAP, DEP
Probioflor (Canada) Lyo-San Inc. (Canada) CAP, DEP
Lacto-B (Canada) Lyo-San Inc. (Canada) CAP, DEP
Probiolomgum (Canada) Lyo-San Inc. (Canada) CAP, DEP
Protec (Canada) Natural Factors Nutritional Products Limited (Canada) CAP, DEP
Enzymes Wobenzym N Mucos Pharma DBP Enzyme
Misc combinations Venastat Leg Vein Health (until 2005) Pharmaton/Boehringer Ingelheim DBP Natural product
Bio ATP Bio Active Nutritional CAP, DEP Vitamin/Herbal
Shenyang Hongyao Film Coated tablet (Canada) Wing Quon Enterprises Ltd. DEP, HMP Herbal
Misc, miscellaneous.Kelley et al.
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In order to create a comprehensive 
listing of phthalate-containing products, 
individual manufacturers would have to 
provide information on their use of phthalates 
in specific product formulations. Such a list 
(similar to those available for other excipients 
such as gelatin or gluten) would not only 
facilitate critical research on the risks and 
safety of phthalate-containing medications but 
also would allow prescribers and consumers to 
select alternative products that are phthalate 
free. Estimates of exposure from these products 
can vary according to manufacturer-specific 
formulation characteristics, including the 
dosage form, dose, date of use, and country 
of manufacture. Researchers, consumers, and 
health care providers may need to contact 
manufacturers directly to confirm the presence 
of phthalates and the amounts used in a 
particular drug product.
Conclusion
Using a combination of resources, we were 
able to identify > 100 drug and dietary supple-
ment products that indicated the use of ortho-
phthalates as excipients, including labels of 
50 RX, 40 OTC, and 26 dietary supplement 
product formulations that listed DEP and/
or DBP (9 contained DBP, and 1 contained 
both DEP and DBP). The potential effects of 
human exposure to these phthalates through 
medications are unknown and warrant fur-
ther investigation. The present findings should 
assist researchers in conducting the neces-
sary studies of risk and safety of phthalates 
in human populations, but such efforts are 
limited by the lack of centralized, comprehen-
sive, and publically available information on 
the presence of phthalates in the full range of 
RX, OTC, and dietary supplement products. 
Future research should pay particular attention 
to the amount of phthalate, specifically DBP, 
used in each dosage form so that estimates of 
exposure from medications and supplements 
can be quantified.
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